Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026

 
• By Eileen Francis

Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.

Lyon France, 3 October 2017: White logo of the french multinational pharmaceutical company Sanofi on their glass office building in Lyon France - Image

More from Rx-to-OTC Switch

More from Health